* age below 18 * life expectancy less than 3 months before covid-19 * resuscitation \> 30 minutes * hypersensitivity to the active substance, to edoxaban or any of its excipients * significantly increased bleeding risk * other indication for anticoagulation beyond covid-19 * gfr \< 15 ml/min * planned transfer of the patient to another clinic within the next 42 days

* age below 18 * life expectancy less than 3 months before covid-19 * resuscitation \> 30 minutes * hypersensitivity to the active substance, to edoxaban or any of its excipients * significantly increased bleeding risk * other indication for anticoagulation beyond covid-19 * gfr \< 15 ml/min * planned transfer of the patient to another clinic within the next 42 days

- age below 18 - life expectancy less than 3 months before covid-19 - resuscitation > 30 minutes - hypersensitivity to the active substance, to edoxaban or any of its excipients - significantly increased bleeding risk - other indication for anticoagulation beyond covid-19 - gfr < 15 ml/min - planned transfer of the patient to another clinic within the next 42 days

- age below 18 - life expectancy less than 3 months before covid-19 - resuscitation > 30 minutes - hypersensitivity to the active substance, to edoxaban or any of its excipients - significantly increased bleeding risk - other indication for anticoagulation beyond covid-19 - gfr < 15 ml/min - planned transfer of the patient to another clinic within the next 42 days